Abstract 3315: Preclinical studies of TSN1611, a potent, selective, and orally bioavailable KRASG12D inhibitor
Shang, Erchang, Zhong, Boyu, Zhang, Tony, Dong, Chunlan, Ma, Shengtang, Yang, Anjiang, Jia, Ziyang, Zheng, Renjuan, Li, Jing, Fu, Han, Lai, Liangbao
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article